Sodium-glucose co-transporter 2 inhibition and acute myocardial infarction: the DAPA-MI and EMPACT-MI trials.

Zaman, Muhammad Adnan; Kalsoom, Sidra

Zaman, Muhammad Adnan; Kalsoom, Sidra.

Affiliation

Zaman MA; Internal Medicine Department, Conemaugh Health System, Johnstown, PA, USA.
Kalsoom S; Cardiology Department, Mercy Health Saint Vincent Medical Center, Toledo, OH, USA.

Expert Rev Clin Pharmacol ; 17(9): 771-775, 2024 Sep.

Article in En | MEDLINE | ID: mdl-39114881

Subject(s)

Myocardial Infarction; Sodium-Glucose Transporter 2 Inhibitors; Sodium-Glucose Transporter 2 Inhibitors/pharmacology; Sodium-Glucose Transporter 2 Inhibitors/administration & dosage; Humans; Myocardial Infarction/drug therapy; Benzhydryl Compounds/pharmacology; Benzhydryl Compounds/adverse effects; Benzhydryl Compounds/administration & dosage; Glucosides/pharmacology; Glucosides/adverse effects; Glucosides/administration & dosage; Hypoglycemic Agents/pharmacology; Hypoglycemic Agents/adverse effects; Hypoglycemic Agents/administration & dosage; Clinical Trials as Topic

Key words

Cardiology; DAPA-MI Trial; EMPACT-MI Trial; SGLT2 inhibitors; acute myocardial infarction; dapagliflozin; empagliflozin

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Sodium-Glucose Transporter 2 Inhibitors / Myocardial Infarction Limits: Humans Language: En Journal: Expert Rev Clin Pharmacol Year: 2024 Document type: Article Affiliation country: United States Country of publication: United kingdom

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google